Business
TNI BioTech and Hubei Qianjiang Pharmaceutical Co., Ltd Supplemental Collaborative Agreement
TNI BioTech and Hubei Qianjiang Pharmaceutical Co., Ltd Supplemental Collaborative Agreement.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n\n\nTNI BioTech and Hubei Qianjiang Pharmaceutical Co., Ltd Supplemental Collaborative Agreement\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nTNI BioTech and Hubei Qianjiang Pharmaceutical Co., Ltd Supplemental Collaborative Agreement\nNew Drug Development Efforts for Novel Cancer Treatments\nPR Newswire\nORLANDO, Fla. and HUBEI, China, Aug. 13, 2014\n\n\n\nORLANDO, Fla. and HUBEI, China, Aug. 13, 2014 /PRNewswire/ -- TNI BioTech, Inc. (OTC: TNIB) (\"TNI\" or the \"Company\") a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, announced today the signing of a supplemental agreement with Hubei Qianjiang Pharmaceutical Co., Ltd (SHSE:600568) ( Qianjiang) China on behalf of Cytocom, TNI BioTech's wholly owed subsidiary.  The signing of the supplemental agreement accelerates clinical trial development in both America and China, for IRT-101 (\"MENK\").  In the hope of moving clinical development forward the parties agreed to the following:  \n\n\nThe parties agree to immediately initiate 3-mo GLP Toxicology Studies within 30 days of the signing of this agreement.  GLP Toxicology Studies Trials will be run in China in accordance with international standards and acceptable to the FDA \nQianjiang Pharmaceutical has raised the funds necessary for clinical development and marketing of MENK. Expenditures are subject to full budget approval by both Qianjiang and Cytocom and will be approved by Mr. Ye Jige, of Qianjiang Pharmaceutical, and, authorized by Noreen Griffin, CEO of TNI BioTech of the United States. \nCytocom and Qianjiang Pharmaceutical will meet immediately with the SFDA to determine that PK and Dosing Trials completed in the US will be acceptable to the SFDA.  All developments and trial results run by Cytocom in the United States or EU will be used for requesting registration approval in China \nBased on PK, Dosing and Existing Trial results in US, Qianjiang pharmaceutical and Dr. Graham Burton and Dr. Joseph Fortuna...